Supernus Pharmaceuticals, Inc. — Third Quarter 2026 Earnings Summary

Supernus Pharmaceuticals reported third-quarter 2026 total revenues of $226.8 million, an 18% increase from the prior year, driven by a 29% rise in combined sales of its four growth products. The company achieved record net sales for Qelbree, GOCOVRI, and ONAPGO, while collaboration revenue from ZURZUVAE reached $41.7 million. Supernus announced that its merger with Indivior Pharmaceuticals is expected to close on November 2, 2026, creating a combined entity named Supernus, Inc. that will trade under the ticker symbol SUPN. Additionally, the company raised its full-year 2026 financial guidance, projecting total revenues between $875 million and $900 million.